Logotype for Aster DM Quality Care Limited

Aster DM Quality Care (ASTERDM) Q1 26/27 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Aster DM Quality Care Limited

Q1 26/27 earnings summary

26 Aug, 2026

Executive summary

  • The merger of Aster DM Healthcare and Quality Care, effective July 1, 2026, created a top 3 hospital chain in India with 39 hospitals and over 10,800 beds, executed with strong cultural integration and zero operational friction.

  • The combined entity demonstrates strong year-on-year revenue growth, operational leverage, and improved margins, driven by increased patient volumes, specialty mix, and digital health initiatives.

  • Strategic priorities include scaling super-specialty care, expanding into Tier 2 and Tier 3 cities, and driving patient-centric innovation.

  • The merger was sanctioned by NCLT and included a name change, with auditors expressing an unmodified review conclusion on the unaudited results.

  • Backed by Blackstone, the merger aims for scale, enhanced metrics, synergies, diversification, and long-term value creation.

Financial highlights

  • Q1 FY 2027 pro forma revenue rose 20% year-on-year to INR 2,597 crore; EBITDA grew 30% to INR 576 crore, with margin expanding 170 bps to 22.2%.

  • Mature units contributed 73% of revenue, growing 19% year-on-year; emerging units saw up to 95% revenue growth and 240% EBITDA growth.

  • Net debt at the combined level is INR 1,162 crore as of June 30, 2026.

  • Normalised PAT (post NCI) for Aster grew 39% YoY to INR 125 crore in Q1 FY 2027.

  • Exceptional merger-related costs impacted net profit, with consolidated net profit at INR 29.28 crore and standalone net loss at INR 14.30 crore.

Outlook and guidance

  • Management maintains guidance of achieving 24%-25% EBITDA margin within two to three years post-merger, targeting FY 2028-2029.

  • Synergy realization is expected to deliver 10%-15% incremental EBITDA based on FY 2024 pro forma, with significant benefits anticipated from scale and operational integration.

  • Planned expansion to add over 4,170 beds, targeting 15,077 total beds by FY30, with 53% in existing and 47% in new facilities.

  • Medical Value Travel (MVT) is targeted to reach double-digit revenue contribution, with growth rates above 50%.

  • Ongoing investments in subsidiaries and associates support strategic growth.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more